Can Immunotherapy Benefit Men with Localized Prostate Cancer
Dr. Tia Higano, a professor in the division of medical oncology at the University of Washington School of Medicine, describes research that suggests that a prostate cancer “vaccine” therapy (sipuleucel-T, or trade name Provenge) may have promise if used in early stage prostate cancer, either alone or in combination with other late-stage investigational medicines. Dr. Higano goes on to discuss how several agents in development may soon give men with advanced prostate cancer more options than ever before, including treatments that may be more powerful in combination than as single-agent therapies. Dr. Higano also explains how the research questions in the near future will focus on discovering how and when to best use various treatments over the course of therapy.
Excerpt from: Can Immunotherapy Benefit Men with Localized Prostate Cancer